Dr. Issam Makhoul
Claim this profileUniversity of Arkansas for Medical Sciences
Studies Breast Cancer
Studies Skin Cancer
6 reported clinical trials
14 drugs studied
Area of expertise
1Breast Cancer
Stage IV
ER negative
PR negative
2Skin Cancer
BRAF positive
Stage IV
Stage III
Affiliated Hospitals
Clinical Trials Issam Makhoul is currently running
RP1 + Nivolumab
for Cancer
This trial tests a modified virus (RP1) and an immune-boosting drug (nivolumab) in adults with advanced or treatment-resistant solid tumors. RP1 kills cancer cells and helps the immune system recognize them, while nivolumab enhances the immune response. Nivolumab has been approved for treating advanced melanoma, renal cell carcinoma, non-small cell lung cancer, and other malignancies.
Recruiting1 award Phase 29 criteria
Tucatinib + Trastuzumab + Pertuzumab
for Breast Cancer
This study is being done to see if tucatinib works better than placebo when given with other drugs to treat participants with HER2-positive breast cancer. A placebo is a pill that looks the same as tucatinib but has no medicine in it. This study will also test what side effects happen when participants take this combination of drugs. A side effect is anything a drug does to the body besides treating your disease. Participants will have cancer that has spread in the body near where it started (locally advanced) and cannot be removed (unresectable) or has spread through the body (metastatic). In this study, all participants will get either tucatinib or placebo. Participants will be assigned randomly to a group. This is a blinded study, so patients and their doctors will not know which group a participant is in. All participants will also get trastuzumab and pertuzumab. These are 2 drugs used to treat this type of cancer.
Recruiting1 award Phase 311 criteria
More about Issam Makhoul
Clinical Trial Related9 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Issam Makhoul has experience with
- Nivolumab
- P10s-PADRE
- Dabrafenib Mesylate
- Trametinib Dimethyl Sulfoxide
- Ipilimumab
- Doxorubicin Hydrochloride
Breakdown of trials Issam Makhoul has run
Breast Cancer
Cutaneous Melanoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Issam Makhoul specialize in?
Issam Makhoul focuses on Breast Cancer and Skin Cancer. In particular, much of their work with Breast Cancer has involved Stage IV patients, or patients who are ER negative.
Is Issam Makhoul currently recruiting for clinical trials?
Yes, Issam Makhoul is currently recruiting for 2 clinical trials in Little Rock Arkansas. If you're interested in participating, you should apply.
Are there any treatments that Issam Makhoul has studied deeply?
Yes, Issam Makhoul has studied treatments such as Nivolumab, P10s-PADRE, Dabrafenib Mesylate.
What is the best way to schedule an appointment with Issam Makhoul?
Apply for one of the trials that Issam Makhoul is conducting.
What is the office address of Issam Makhoul?
The office of Issam Makhoul is located at: University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205 United States. This is the address for their practice at the University of Arkansas for Medical Sciences.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.